SIGA vs. ARCT, COGT, PRTC, YMAB, AUPH, IRON, SVRA, WVE, SAGE, and DNTH
Should you be buying SIGA Technologies stock or one of its competitors? The main competitors of SIGA Technologies include Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Savara (SVRA), Wave Life Sciences (WVE), Sage Therapeutics (SAGE), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical preparations" industry.
SIGA Technologies (NASDAQ:SIGA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
In the previous week, Arcturus Therapeutics had 8 more articles in the media than SIGA Technologies. MarketBeat recorded 19 mentions for Arcturus Therapeutics and 11 mentions for SIGA Technologies. Arcturus Therapeutics' average media sentiment score of 0.68 beat SIGA Technologies' score of 0.67 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.
55.4% of SIGA Technologies shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 2.2% of SIGA Technologies shares are owned by company insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
SIGA Technologies has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.
SIGA Technologies has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500.
Arcturus Therapeutics received 422 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 65.39% of users gave Arcturus Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote.
SIGA Technologies has a net margin of 50.48% compared to Arcturus Therapeutics' net margin of -81.59%. SIGA Technologies' return on equity of 51.97% beat Arcturus Therapeutics' return on equity.
Arcturus Therapeutics has a consensus target price of $64.86, suggesting a potential upside of 118.08%. Given Arcturus Therapeutics' higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than SIGA Technologies.
Summary
Arcturus Therapeutics beats SIGA Technologies on 11 of the 17 factors compared between the two stocks.
Get SIGA Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SIGA Technologies Competitors List
Related Companies and Tools
